ProMACE/CytaBOM方案治疗难治性或复发性非霍奇金淋巴瘤的疗效观察

Effect of ProMACE/CytaBOM regimen in treatment of refractory or relapse non-Hodgkin's lymphoma

目的:探讨ProMACE/CytaBOM方案治疗难治性和(或)复发性非霍奇金淋巴瘤(NHL)的疗效。方法:采用ProMACE/CytaBOM方案治疗18例难治性和(或)复发性NHL患者,其中难治性NHL患者8例,复发性NHL患者10例。结果:5例难治性和(或)复发性NHL患者达到完全缓解(CR率为27.8％),4例达部分缓解(PR率为22.2％),总有效率为50.0％;目前12例仍生存,其中生存最长者26个月(2例),仍处于CR期。毒副作用主要为消化道症状、轻度肝功能异常以及骨髓抑制。结论:ProMACE/CytaBOM方案对部分难治性和(或)复发性NHL患者仍有效,毒副作用较轻,可用于治疗对其他化疗方案无效的难治性和(或)复发性NHL。

Objective:To elucidate the effect of ProMACE/CytaBOM regimen in treatment of refractory and relapse non-Hodgkin's lymphoma. Method: 18 patients with refractory or relapse non-Hodgkin's lymphoma (8 refractory NHL patients,10 relapsing NHL patients )were treated with ProMACE/CytaBOM regimen. Result:The rate of complete remission was 27. 8% (5/18), the rate of partial remission was 22. 2% (4/18), and the overall response rate was 50.0%. Main toxicity were myelosupression and neutropenia. Conclusion: ProMACE/CytaBOM regimen could be employed in treatment of the patients with refractory or relapsing non-Hodgkin's lymphoma who were not respond to other regimens, and the regimen was safe.